-Business Insider
Confidence Boost From Ingrezza Sales: Analyst Upgrades Neurocrine Biosciences
BMO Capital Markets has upgraded Neurocrine Biosciences Inc (NASDAQ: NBIX) from Underperform to Market Perform, with a price target of $96,
Related Posts
On Friday April 5, 2024, Legend Biotech Reported CARVYKTI Becomes The First And Only BCMA-Targeted CAR-T Cell Therapy Approved By The FDA For Second-Line Treatment Of Multiple Myeloma
New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapseLegend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, announced
A Look Into Trade Desk Inc’s Price Over Earnings
In the current session, the stock is trading at $76.81, after a 0.05% spike. Over the past month,…
